Exploring Three High Growth Tech Stocks in Europe

In This Article:

As European markets navigate the challenges of new U.S. trade tariffs and fluctuating economic indicators, the pan-European STOXX Europe 600 Index recently experienced a decline of about 1.4%, reflecting broader market sentiment impacted by geopolitical tensions and inflation concerns. In this environment, identifying high-growth tech stocks requires a focus on companies with strong fundamentals and innovative capabilities that can adapt to shifting market dynamics while maintaining robust growth potential.

Top 10 High Growth Tech Companies In Europe

Name

Revenue Growth

Earnings Growth

Growth Rating

Pharma Mar

24.24%

40.82%

★★★★★★

Archos

24.45%

65.92%

★★★★★★

Yubico

20.88%

26.53%

★★★★★★

Truecaller

20.10%

24.70%

★★★★★★

Elicera Therapeutics

63.53%

97.24%

★★★★★★

XTPL

97.45%

117.95%

★★★★★★

Devyser Diagnostics

26.38%

95.42%

★★★★★★

Ascelia Pharma

46.09%

66.93%

★★★★★★

CD Projekt

33.68%

36.76%

★★★★★★

Elliptic Laboratories

49.76%

88.21%

★★★★★★

Click here to see the full list of 238 stocks from our European High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

argenx

Simply Wall St Growth Rating: ★★★★★☆

Overview: argenx SE is a commercial-stage biopharmaceutical company that focuses on developing therapies for autoimmune diseases across multiple regions, including the United States, Japan, China, and the Netherlands, with a market capitalization of €33.15 billion.

Operations: argenx SE generates revenue primarily from its biotechnology segment, which amounts to $2.25 billion. The company focuses on developing therapies for autoimmune diseases across multiple regions, including the United States, Japan, China, and the Netherlands.

Argenx SE has demonstrated a robust turnaround, reporting a significant revenue increase to $2.25 billion in 2024 from $1.27 billion the previous year, alongside transitioning from a net loss of $295 million to a net income of $833 million. This financial rebound is underscored by an impressive annual earnings growth forecast at 28.3%. The company's commitment to innovation is evident in its recent clinical trial announcements, which could enhance its competitive edge within the biotech sector. These developments not only reflect Argenx's strategic agility but also position it well for sustained growth, leveraging advanced therapies that meet critical healthcare needs.

ENXTBR:ARGX Revenue and Expenses Breakdown as at Apr 2025
ENXTBR:ARGX Revenue and Expenses Breakdown as at Apr 2025

CD Projekt

Simply Wall St Growth Rating: ★★★★★★

Overview: CD Projekt S.A., along with its subsidiaries, focuses on developing, publishing, and digitally distributing video games for PCs and consoles in Poland, with a market capitalization of PLN20.98 billion.